Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab (AK104) in Metastatic Nasopharyngeal Carcinoma
NCT04220307Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Apr 2020
- Primary completion
- May 2021
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in nasopharyngeal carcinoma (NPC), sponsored by Akeso, Inc.. Started Apr 2020; status: completed.
02
Drugs
cadonilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04220307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220307.